Clinical Trial Update: Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease [Phase 1, Phase 2]

View source ↗

Summary

Open-label extension study evaluating safety and tolerability of WVE-120101 in Huntington's disease was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• WVE-120101 (WVE-120101)

Snippet

Sponsor: Wave Life Sciences Ltd. | Conditions: Huntington Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-02-09